BA drops to $197.72 this week — down 5.7% on the week and nearly 8% over the past month — widening the gap between where the stock trades and where the Street thinks it belongs.
The catalyst for the week's move is the most concrete development on the analyst side. Jefferies cut its price target from $295 to $265 on September 21, while keeping a Buy rating — the kind of trimming that signals less conviction even when the label doesn't change. That came one day after BofA reiterated its Buy with a $270 target, a rare same-week contrast that illustrates just how divided the execution story has become. The broader consensus still leans heavily bullish: 17 Buy and 5 Outperform ratings, zero Sells, and a mean target around $274. At $197.72, that implies roughly 38% upside — a gap so wide it functions less as a signal of optimism than as a measure of how much the market discounts the Street's confidence. This is the same tension flagged in last week's note, now sharpened by the Jefferies cut: analysts believe in the recovery, but the stock keeps pricing in more risk.
The lending market offers no amplifying pressure. Short interest is a modest 2.2% of free float — up about 12% over the past month in share terms, but still firmly in the low-significance range. Borrowing remains nearly effortless: availability is above 5,000% of short interest, meaning there are roughly 50 shares available to borrow for every one currently lent out. Cost to borrow has actually eased, falling 11% on the week to 0.34% — the lowest reading in the 30-day window. The ORTEX short score sits at 32.8, unchanged in tone across the past two weeks. None of this points to a short-side story; the modest buildup in shorts is better read as cautious hedging than a conviction bet against the recovery.
Options positioning is similarly undramatic. The put/call ratio is 0.88, fractionally below its 20-day average of 0.89 and nearly a half standard deviation light on the put side. That is not a defensive posture. Options traders are not loading up on downside protection despite the week's price action, which cuts against any narrative of panic selling. The PE multiple has compressed about 22 points over the past month to roughly 72x — still elevated, but the direction of travel reflects a market repricing the recovery timeline rather than abandoning it. EV/EBITDA at 25.4x is down about 1.5 turns over the same period. Valuation is de-rating gradually, not collapsing.
Factor scores tell a two-speed story. EPS momentum over both 30 and 90 days ranks in the 97th percentile — Boeing has been beating estimates at a rate almost no large-cap aerospace name can match. The EPS surprise rank is in the 93rd percentile. Those are strong numbers. Against them sits a forward earnings growth score in the 11th percentile, reflecting analyst caution about whether the recent cadence is sustainable beyond the current recovery cycle. That is precisely the bull/bear tension the bears articulate: a backlog that is unambiguously large, but supply-chain execution and defense-budget exposure that could slow the conversion of orders to cash.
Peers fared better on the week. GE gained 4% and Safran added 3%, while Rolls-Royce rose more than 4%. Curtiss-Wright fell 2.2%, closer to Boeing's move, but the broader picture is that BA underperformed the engine and propulsion names that often trade alongside it. That divergence is worth watching into the October 21 earnings call — the last time BA reported, the stock was flat on the day but up 12% over the following five days, suggesting the market tends to reward the number if it clears the bar.
The October 21 print is now the only near-term event that can close the analyst-versus-market gap — the question is whether production data and cash flow guidance will be enough to revive the stock's September momentum, or whether the Jefferies target cut is the first of several.
See the live data behind this article on ORTEX.
Open BA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
